234 related articles for article (PubMed ID: 35975404)
1. Efficacy and safety of vibegron for the treatment of irritable bowel syndrome in women: Results of a randomized, double-blind, placebo-controlled phase 2 trial.
Lacy BE; King J; Shortino D; Schaumburg C; Haag-Molkenteller C; Chey WD
Neurogastroenterol Motil; 2022 Dec; 34(12):e14448. PubMed ID: 35975404
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials.
Brenner DM; Fogel R; Dorn SD; Krause R; Eng P; Kirshoff R; Nguyen A; Crozier RA; Magnus L; Griffin PH
Am J Gastroenterol; 2018 May; 113(5):735-745. PubMed ID: 29545635
[TBL] [Abstract][Full Text] [Related]
3. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation.
Rao S; Lembo AJ; Shiff SJ; Lavins BJ; Currie MG; Jia XD; Shi K; MacDougall JE; Shao JZ; Eng P; Fox SM; Schneier HA; Kurtz CB; Johnston JM
Am J Gastroenterol; 2012 Nov; 107(11):1714-24; quiz p.1725. PubMed ID: 22986440
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of olorinab, a full agonist of the cannabinoid receptor 2, for the treatment of abdominal pain in patients with irritable bowel syndrome: Results from a phase 2b randomized placebo-controlled trial (CAPTIVATE).
Chang L; Cash BD; Lembo A; Kunkel DC; English BA; Lindstrom B; Gu G; Skare S; Gilder K; Turner S; Cataldi F; Lipkis D; Tack J
Neurogastroenterol Motil; 2023 May; 35(5):e14539. PubMed ID: 36740814
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of purified clinoptilolite-tuff treatment in patients with irritable bowel syndrome with diarrhea: Randomized controlled trial.
Anderle K; Wolzt M; Moser G; Keip B; Peter J; Meisslitzer C; Gouya G; Freissmuth M; Tschegg C
World J Gastroenterol; 2022 Dec; 28(46):6573-6588. PubMed ID: 36569277
[TBL] [Abstract][Full Text] [Related]
6. Rifaximin Treatment for Individual and Multiple Symptoms of Irritable Bowel Syndrome With Diarrhea: An Analysis Using New End Points.
Lacy BE; Chang L; Rao SSC; Heimanson Z; Sayuk GS
Clin Ther; 2023 Mar; 45(3):198-209. PubMed ID: 36922331
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 12-Week, Placebo-Controlled Phase 3 Trial (T3MPO-1).
Chey WD; Lembo AJ; Rosenbaum DP
Am J Gastroenterol; 2020 Feb; 115(2):281-293. PubMed ID: 31934897
[TBL] [Abstract][Full Text] [Related]
8. Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial.
Ducrotte P; Dapoigny M; Bonaz B; Siproudhis L
Aliment Pharmacol Ther; 2005 Feb; 21(4):435-44. PubMed ID: 15709995
[TBL] [Abstract][Full Text] [Related]
9. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety.
Chey WD; Lembo AJ; Lavins BJ; Shiff SJ; Kurtz CB; Currie MG; MacDougall JE; Jia XD; Shao JZ; Fitch DA; Baird MJ; Schneier HA; Johnston JM
Am J Gastroenterol; 2012 Nov; 107(11):1702-12. PubMed ID: 22986437
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Peppermint Oil in a Randomized, Double-Blind Trial of Patients With Irritable Bowel Syndrome.
Weerts ZZRM; Masclee AAM; Witteman BJM; Clemens CHM; Winkens B; Brouwers JRBJ; Frijlink HW; Muris JWM; De Wit NJ; Essers BAB; Tack J; Snijkers JTW; Bours AMH; de Ruiter-van der Ploeg AS; Jonkers DMAE; Keszthelyi D
Gastroenterology; 2020 Jan; 158(1):123-136. PubMed ID: 31470006
[TBL] [Abstract][Full Text] [Related]
11. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study.
Dove LS; Lembo A; Randall CW; Fogel R; Andrae D; Davenport JM; McIntyre G; Almenoff JS; Covington PS
Gastroenterology; 2013 Aug; 145(2):329-38.e1. PubMed ID: 23583433
[TBL] [Abstract][Full Text] [Related]
12. Optimal dose of ramosetron in female patients with irritable bowel syndrome with diarrhea: A randomized, placebo-controlled phase II study.
Fukudo S; Matsueda K; Haruma K; Ida M; Hayase H; Akiho H; Nakashima Y; Hongo M
Neurogastroenterol Motil; 2017 Jun; 29(6):. PubMed ID: 28205278
[TBL] [Abstract][Full Text] [Related]
13. Abdominal Pain Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea.
Lembo A; Rao SSC; Heimanson Z; Pimentel M
Clin Transl Gastroenterol; 2020 Mar; 11(3):e00144. PubMed ID: 32352714
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 26-Week, Placebo-Controlled Phase 3 Trial (T3MPO-2).
Chey WD; Lembo AJ; Yang Y; Rosenbaum DP
Am J Gastroenterol; 2021 Jun; 116(6):1294-1303. PubMed ID: 33337659
[TBL] [Abstract][Full Text] [Related]
15. Tenapanor Treatment of Patients With Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, Randomized, Placebo-Controlled Efficacy and Safety Trial.
Chey WD; Lembo AJ; Rosenbaum DP
Am J Gastroenterol; 2017 May; 112(5):763-774. PubMed ID: 28244495
[TBL] [Abstract][Full Text] [Related]
16. Linaclotide in irritable bowel syndrome with constipation: A Phase 3 randomized trial in China and other regions.
Yang Y; Fang J; Guo X; Dai N; Shen X; Yang Y; Sun J; Bhandari BR; Reasner DS; Cronin JA; Currie MG; Johnston JM; Zeng P; Montreewasuwat N; Chen GZ; Lim S
J Gastroenterol Hepatol; 2018 May; 33(5):980-989. PubMed ID: 29319191
[TBL] [Abstract][Full Text] [Related]
17. Randomised clinical trial: pregabalin vs placebo for irritable bowel syndrome.
Saito YA; Almazar AE; Tilkes KE; Choung RS; Van Norstrand MD; Schleck CD; Zinsmeister AR; Talley NJ
Aliment Pharmacol Ther; 2019 Feb; 49(4):389-397. PubMed ID: 30663077
[TBL] [Abstract][Full Text] [Related]
18. Randomized Clinical Trial: Crofelemer Treatment in Women With Diarrhea-Predominant Irritable Bowel Syndrome.
Nee J; Salley K; Ludwig AG; Sommers T; Ballou S; Takazawa E; Duehren S; Singh P; Iturrino J; Katon J; Lee HN; Rangan V; Lembo AJ
Clin Transl Gastroenterol; 2019 Dec; 10(12):e00110. PubMed ID: 31800542
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of 5-HT4 Receptor Agonist Minesapride for Irritable Bowel Syndrome with Constipation in a Randomized Controlled Trial.
Fukudo S; Nakamura M; Hamatani T; Kazumori K; Miwa H
Clin Gastroenterol Hepatol; 2021 Mar; 19(3):538-546.e8. PubMed ID: 32184185
[TBL] [Abstract][Full Text] [Related]
20. Randomised clinical trial: minesapride vs placebo for irritable bowel syndrome with predominant constipation.
Hamatani T; Fukudo S; Nakada Y; Inada H; Kazumori K; Miwa H
Aliment Pharmacol Ther; 2020 Aug; 52(3):430-441. PubMed ID: 32583907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
